Literature DB >> 22713090

Provision of community-wide benefits in public health intervention research: the experience of investigators conducting research in the community setting in South Asia.

Holly A Taylor1, Maria W Merritt.   

Abstract

BACKGROUND: This article describes the types of community-wide benefits provided by investigators conducting public health research in South Asia as well as their self-reported reasons for providing such benefits.
METHODS: We conducted 52 in-depth interviews to explore how public health investigators in low-resource settings make decisions about the delivery of ancillary care to research subjects. In 39 of the interviews respondents described providing benefits to members of the community in which they conducted their study. We returned to our narrative dataset to find answers to two questions: What types of community-wide benefits do researchers provide when conducting public health intervention studies in the community setting, and what reasons do researchers give when asked why they provided community-wide benefits?
FINDINGS: The types of community-wide benefits delivered were directed to the health and well-being of the population. The most common types of benefits delivered were the facilitation of access to health care for individuals in acute medical need and emergency response to natural disasters. Respondents' self-reported reasons when asked why they provided such benefits fell into 2 general categories: intrinsic importance and instrumental importance.
© 2012 Blackwell Publishing Ltd.

Mesh:

Year:  2012        PMID: 22713090     DOI: 10.1111/j.1471-8847.2012.00333.x

Source DB:  PubMed          Journal:  Dev World Bioeth        ISSN: 1471-8731            Impact factor:   2.294


  2 in total

Review 1.  The potential exploitation of research participants in high income countries who lack access to health care.

Authors:  Rafael Dal-Ré; Annette Rid; Ezekiel Emanuel; David Wendler
Journal:  Br J Clin Pharmacol       Date:  2016-02-29       Impact factor: 4.335

2.  Protections for clinical trials in low and middle income countries need strengthening not weakening.

Authors:  Rafael Dal-Ré; Paul Ndebele; Elizabeth Higgs; Nelson Sewankambo; David Wendler
Journal:  BMJ       Date:  2014-07-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.